Synopsis:
– The company reported rise of 830% in Net Profit on Q-o-Q basis at Rs 23.29 crore
– Company’s revenue for Q1FY26 is Rs 299.91 crores
– Company recently completed seven export-sourcing assignments totalling Rs 299.91 crores
– Company had earlier secured a major Rs 517 crore global sourcing mandate from Thailand-based Fortune Sagar Impex Company Limited
Welcure Drugs & Pharmaceuticals Ltd, today announced its financial results for the quarter ended June 30, 2025 (Q1FY26). The company has reported a robust financial performance in the first quarter of FY26, driven by its strategic foray into fee-based, export-oriented sourcing services.
Welcure’s revenue from operations rose sharply to Rs 299.91 crores in Q1FY26, up from Rs 21.21 crores previous quarter Q4FY25, making it about 1300% rise on Q-o-Q basis. The company reported Net Profit of Rs 23.29 crores in Q1FY26 as against a net loss of Rs 0.34 crores in the same period last year Q1FY25. The company reported almost 830% rise in Net Profit on Q-o-Q basis when compared to Net Profit of Rs 2.5 crore registered in Q4FY25 that ended on March 31, 2025. Earnings per share (EPS) stood at Rs 2.07 in Q1FY26 as compared to Rs -0.26 in Q1FY25.
Speaking on the stellar financial performance of Q1FY26, the management of the company commented, “The strong financial performance in Q1FY26, is a reflection of our business strategies, meticulous decisions and our focused transition to a fee-based, asset-light model. We are committed to sustaining this performance through efficient supply chain management and product diversification.”
The company has recently completed seven export-sourcing assignments totalling Rs 299.91 crores, acting solely as a procurement agent on behalf of international buyers. The company earns a fixed 5% commission on these transactions, with no exposure to inventory, logistics, or working capital risks, preserving its debt-free structure. This shift toward fee-based export services has significantly enhanced Welcure’s revenue profile, with commission income recognized in accordance with Ind AS 115 on receipt basis.
Additionally, Welcure had earlier secured a major Rs 517 crore global sourcing mandate from Thailand-based Fortune Sagar Impex Company Limited, expected to contribute an estimated Rs 25.85 crores in service income during FY26.
The company implemented important leadership decisions to streamline governance for robust growth. The company appointed Mr Rabi Thakor as an Additional Non-Executive Non-Independent Director. The company also appointed Mr. Yogeshkumar Prajapati and Mrs. Bhumika Pradhan joined as Additional Independent Directors.
Incorporated in 1992, Welcure Drugs & Pharmaceuticals Ltd is an established pharmaceutical company in India, engaged in the manufacture and trade of a wide range of healthcare formulations. With a focus on quality, compliance, and global integration, Welcure continues to expand its presence in both domestic and international markets.
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
